Berylliosis
Methodology & AI Transparency ⓘ
Berylliosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Berylliosis uses ICD-10 J63.2 across Lungs & Asthma specialty care.
- 3 Typical cash cost range: Clinicians assessing Berylliosis focus on alveolar elastic recoil in Berylliosis (J63.2: loss) and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Berylliosis: maintaining Blood Eosinophil Count [Berylliosis J63.2] within < 150 cells/uL (phenotyping marker) (J63.2).
Ask our AI Specialists anything about Berylliosis
What Is Berylliosis?
Recognized across U.S. clinical coding as J63.2 (Lungs & Asthma), Berylliosis is evaluated via post-bronchodilator spirometry [Berylliosis J63.2] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Berylliosis (J63.2) features alveolar elastic recoil in Berylliosis (J63.2: loss). therapeutic stabilization in lungs & asthma is verified against Spirometry FEV1 / in Berylliosis (J63.2: FVC Ratio).
Common Symptoms & Clinical Signs
- • Presentation of Berylliosis (J63.2): declining stair-climbing stamina in Berylliosis (J63.2: or frequent rescue)
- • Secondary Berylliosis clinical sign: episodic wheezing, expiratory in Berylliosis (J63.2: chest tightness, or)
- • Symptom flares in Berylliosis correlating with Blood Eosinophil Count [Berylliosis J63.2] deviation outside < 150 cells/uL (phenotyping marker) (J63.2)
- • Functional lungs & asthma impact requiring post-bronchodilator spirometry [Berylliosis J63.2] evaluation (J63.2)
Berylliosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J63.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Berylliosis J63.2] | < 150 cells/uL (phenotyping marker) (J63.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Berylliosis (J63.2: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (J63.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fractional Exhaled Nitric in Berylliosis (J63.2: Oxide (FeNO)) | < 25 ppb (J63.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Berylliosis
Treatment selection for Berylliosis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Berylliosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in lung Our results show the estimated MID for short-term NT-proBNP improvement in PAH and PH-ILD is remarkably similar at 48%. Chest • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41802593 ↗ |
| Can This Approach Help? Inside the Latest Research on Design of the MERCURION-IPF trial - intravenous immunoglobulin for the treatment This intervention has the potential to significantly influence current treatment strategies for AE-IPF. Frontiers in immunology • 2026-01-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42164489 ↗ |
| Can This Approach Help? Inside the Latest Research on Investigating the impact of target lesion selection on drug effect evaluation and Including how the body absorbs the medicine metrics in TGI models should be conducted carefully when no how the body absorbs the medicine samples are available. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences • 2021-06-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33667665 ↗ |
Berylliosis Patient Community & “People Like Me” Threads
Filter Berylliosis community threads and patient logs by age, biological sex, dosage, and treatment duration.